Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Ingram

Showing results (71-80 of 143) with videos related to

Pageof 15
Sort By:
BMJ Open|March 23, 2023
Meaning of Family Reported Outcome Measure (FROM-16) severity score bands: a cross-sectional online study in the UKRubina Shah, Andrew Y Finlay, Sam M Salek, et al.
The British Journal of Dermatology|May 20, 2023
Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativaJazzmin C Williams, Raed Alhusayen, Sandra Guilbault, et al.
BMC Dermatology|April 19, 2015
Validation of the global resource of eczema trials (GREAT database)Helen Nankervis, Alison Devine, Hywel C Williams, et al.
The British Journal of Dermatology|March 27, 2023
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countriesJui Vyas, Jeffrey R Johns, Faraz M Ali, et al.
International Journal of Sports Physiology and Performance|January 11, 2013
Electrostimulation's enhancement of recovery during a rugby preseasonC Martyn Beaven, Christian Cook, David Gray, et al.
The British Journal of Dermatology|April 2, 2025
Psychometric Validation and Interpretation Thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) Questionnaire Using Pooled Data from the Phase 3 BE HEARD I & II Trials of Bimekizumab in Hidradenitis SuppurativaJoslyn S Kirby, Linnea Thorlacius, Jérémy Lambert, et al.
Journal of Parkinson'S Disease|April 8, 2026
Beyond the burden: Measuring the quality of life impact of Parkinson's on family members/partners using FROM-16Rubina Shah, Sam Salek, Faraz M Ali, et al.
Pharmacoeconomics|February 9, 2017
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Christopher Carroll, John W Stevens, et al.
Diabetes, Obesity & Metabolism|November 25, 2024
Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross-sectional studyRubina Shah, Andrew Y Finlay, Faraz M Ali, et al.
The British Journal of Dermatology|May 23, 2022
Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trialsAmit Garg, Carla Zema, Katherine Kim, et al.
Pageof 15

Showing results (71-80 of 143) with videos related to

Sort By:
Pageof 15
BMJ Open|March 23, 2023
Meaning of Family Reported Outcome Measure (FROM-16) severity score bands: a cross-sectional online study in the UKRubina Shah, Andrew Y Finlay, Sam M Salek, et al.
The British Journal of Dermatology|May 20, 2023
Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativaJazzmin C Williams, Raed Alhusayen, Sandra Guilbault, et al.
BMC Dermatology|April 19, 2015
Validation of the global resource of eczema trials (GREAT database)Helen Nankervis, Alison Devine, Hywel C Williams, et al.
The British Journal of Dermatology|March 27, 2023
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countriesJui Vyas, Jeffrey R Johns, Faraz M Ali, et al.
International Journal of Sports Physiology and Performance|January 11, 2013
Electrostimulation's enhancement of recovery during a rugby preseasonC Martyn Beaven, Christian Cook, David Gray, et al.
The British Journal of Dermatology|April 2, 2025
Psychometric Validation and Interpretation Thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) Questionnaire Using Pooled Data from the Phase 3 BE HEARD I & II Trials of Bimekizumab in Hidradenitis SuppurativaJoslyn S Kirby, Linnea Thorlacius, Jérémy Lambert, et al.
Journal of Parkinson'S Disease|April 8, 2026
Beyond the burden: Measuring the quality of life impact of Parkinson's on family members/partners using FROM-16Rubina Shah, Sam Salek, Faraz M Ali, et al.
Pharmacoeconomics|February 9, 2017
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Christopher Carroll, John W Stevens, et al.
Diabetes, Obesity & Metabolism|November 25, 2024
Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross-sectional studyRubina Shah, Andrew Y Finlay, Faraz M Ali, et al.
The British Journal of Dermatology|May 23, 2022
Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trialsAmit Garg, Carla Zema, Katherine Kim, et al.
Pageof 15